Key result
The beneficial effect of intensive blood pressure control on heart failure events was not significantly modified by baseline renal function, despite an early decline in eGFR.
Why the study?
Does intensive blood pressure control reduce future heart failure events in non-diabetic patients with hypertension and high cardiovascular risk across the spectrum of baseline renal function?
Does intensive blood pressure control reduce future heart failure events in non-diabetic patients with hypertension and high cardiovascular risk across the spectrum of baseline renal function?
Answers are grounded in this paper and cite their sources.
Worsening renal function during intensive blood pressure control does not negate its benefits in preventing heart failure, suggesting antihypertensive therapy should not be discontinued solely due to an initial creatinine rise.
This article refers to ‘Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy’ by M. Vaduganathan et al., published in this issue on pages 384–392. Cardiovascular disease and chronic kidney disease (CKD) have a complex relationship. Reduced estimated glomerular filtration rate (eGFR) and albuminuria are major independent predictors of cardiovascular morbidity and mortality in the general population.1 Moreover, patients with CKD are more likely to die from cardiovascular disease than by progressing to end-stage renal disease.2 As heart failure has been shown to be one of the major unfavourable consequences among patients with CKD,3, 4 identifying the interventions to prevent heart failure is of paramount importance. Hypertension is one of the major risk factors for both CKD and heart failure in the general population.5, 6 As hypertension is a modifiable risk factor, several clinical trials have tested and proved the hypothesis that an intensive blood pressure (BP)-lowering strategy reduces all-cause mortality and the risk of cardiovascular events including heart failure.7, 8 This is also true for patients with CKD. Malhotra et al.9 conducted a meta-analysis of 18 randomized hypertension trials with mortality data in adults with stages 3 to 5 CKD, and found that a more intensive BP-lowering strategy decreased the risk of all-cause death, and there was a correlation between the decrease in systolic BP (SBP) achieved by treatment and mortality risk. The SPRINT (Systolic Blood Pressure Intervention Trial) study is one of the important contemporary studies that investigated the prognostic implications of aggressive BP control among those at high risk for cardiovascular events. SPRINT was a randomized clinical trial in which over 9000 non-diabetic individuals over the age of 50 years with hypertension, high cardiovascular risk, and eGFR between 20 and 60 mL/min/1.73 m2 were randomized to two groups. The standard treatment group had an SBP target of <140 mmHg and that of the intensive treatment group was <120 mmHg. The safety and efficacy endpoints were evaluated. The primary endpoint was a composite of myocardial infarction, acute coronary syndrome, stroke, acute heart failure, or death from cardiovascular-related causes. The study was stopped early because of the significant beneficial effect in the intensive treatment group when compared to the standard treatment group, and a lower rate of heart failure was one of the main drivers of this difference.7 On the other hand, approximately 10.3% of the participants randomized to the intensive treatment group had a ≥20% early decline in eGFR (baseline to 6 months), which is significantly more than 4.4% in those assigned to standard treatment,10 and the intensive treatment group was associated with a 1.7-fold higher risk of acute kidney injury or failure.7 Among participants with hypertension and without CKD at baseline, intensive treatment caused a 3.5-fold higher hazard of incident CKD, which is defined as eGFR reduction of ≥30% to a confirmed level of <60 mL/min per 1.73 m2, and this difference in eGFR was retained during follow-up.11 These findings raise the question of whether the association between intensive BP-lowering therapy and lower heart failure risk can be retained even in those with impaired renal function at baseline. In this issue of the Journal, Vaduganathan et al.12 investigated the association between baseline eGFR and urine albumin-to-creatinine ratio and the risk of future heart failure events. The possibility of modifying the impact of intensive BP control on future heart failure risk by baseline renal impairment using the SPRINT dataset was also assessed. They found a non-linear but positive association between eGFR, albumin-to-creatinine ratio, and future heart failure risk, and also found that the beneficial effect of intensive BP control on heart failure events was not significantly modified by baseline renal function, even though it appears to be attenuated in those with severe renal dysfunction. This finding is intriguing and in a sense confusing, given the strong association between poor renal function and heart failure risk. However, what is shown in this study is consistent with the contemporary understanding of the prognostic impact of change in renal function in patients with heart failure. It has been assumed that an increase in creatinine (i.e. decrease in eGFR), which is also known as worsening renal function (WRF), is generally associated with poor prognosis in patients with heart failure; however, recent accumulating evidence has challenged this relationship by demonstrating that WRF is not always associated with deleterious outcomes, and the prognostic implication of WRF is strongly dependent on the clinical context in which it occurs.13 For instance, WRF occurring during favourable ongoing diuresis and improvement in heart failure status is not associated with worse prognosis in patients with acute heart failure.14 In the setting of chronic heart failure, WRF occurring during the initiation of neurohormonal blockers is also not associated with subsequent poor prognosis. On the contrary, it is even associated with better prognosis when compared to those without WRF.15 It is also notable that a recent sub-analysis of PARADIGM-HF shows that treatment with sacubitril/valsartan is associated with an increase in albumin-to-creatinine ratio but less decrease in eGFR and better prognosis during 48 months of follow-up.16 All these study results imply that WRF occurring during the treatment with a clear beneficial effect does not lead to poor prognosis. This notion, however, has been applied to patients who already have heart failure, and the present study demonstrated the possibility that it can be expanded to those without heart failure and their future heart failure risk. As declining renal function is not desirable during the treatment of hypertension, it may urge the physicians to discontinue or reduce antihypertensive prescriptions, especially in patients with pre-existing renal dysfunction. The significance of this study is clear; discontinuation of antihypertensive drugs only because of an increase in creatinine is not recommended. This message is also supported by the data showing consistent results from the sub-analysis of the ACCORD study, which showed that although an initial >30% serum creatinine increase is associated with adverse clinical outcomes, it does not lead to a higher risk of cardiovascular and renal outcomes in patients receiving intensive treatment when compared with standard antihypertensive therapy in patients with type 2 diabetes mellitus.17 These results consistently show the importance of interpreting changes in renal function within the appropriate clinical context and correctly assessing its risk and determining treatment strategies accordingly. On the other hand, the relatively short duration of follow-up in SPRINT and the fact that there were very few end-stage kidney disease events during follow-up should be acknowledged as important limitations. The long-term kidney effects of early eGFR decline due to intensive SBP lowering remains to be determined. In addition, the BP lowering in each arm was not detailed, and it is unclear if there is any particular antihypertensive drug that is strongly associated with lower heart failure events. Although this study is insightful, the pathophysiological background of the association between changes in renal function and cardiovascular disease needs to be clarified. Moreover, novel and promising BP-lowering drugs that reduce the risk for cardiovascular events while exerting favourable effects on renal function, such as sodium–glucose co-transporter-2 inhibitors,18 should be tested in this high-risk population, as it may provide us with further knowledge on complicated associations. This work was partially supported by JSPS KAKENHI grant number 18K15862. Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Ito et al. (2020) conducted an editorial in Hypertension and high cardiovascular risk (n=9,000). Intensive blood pressure control vs. Standard treatment (SBP target <140 mmHg) was evaluated on Composite of myocardial infarction, acute coronary syndrome, stroke, acute heart failure, or death from cardiovascular-related causes. The beneficial effect of intensive blood pressure control on heart failure events was not significantly modified by baseline renal function, despite an early decline in eGFR.
Synapse has enriched 10 related papers. Consider them for comparative context: